Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. We are interested in knowing if a medication named Ondansetron can help ease or prevent symptoms associated with opioid withdrawal. We are also interested in knowing if a similar (but more potent FDA-approved drug, palonosetron) can more effectively treat withdrawal symptoms with or without combination with an antihistamine called hydroxyzine (vistaril).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Stanford University
• Treatments: Hydroxyzine; Ondansetron; Palonosetron

Criteria

Inclusion Criteria:

• Healthy males

• Ages 18-35

• No allergies to morphine or palonosetron

• No history of addiction or substance abuse

Exclusion Criteria:

• Female

• Younger than 18 or older than 35

• History of substance abuse

• Raynaud's disease or coronary artery disease

• Allergies to morphine or palonosetron